Literature DB >> 27170390

Pathogenesis, Diagnosis and Treatment of Hemochromatosis.

Heinz Zoller1, Benjamin Henninger.   

Abstract

Hemochromatosis is a common cause of chronic liver disease and HFE genotyping allows decisive and non-invasive diagnosis. Molecular and clinical genetic studies have led to the identification of genes other than HFE in patients with inherited diseases associated with increased hepatic iron storage that can cause hemochromatosis, which adds complexity to a diagnostic approach to patients with suspected hemochromatosis. Despite major advances in genetics, hepatic iron quantification by non-invasive methods therefore remains the key to the diagnosis of hemochromatosis. Although associated with homozygosity for the C282Y polymorphism in the HFE gene in >80% of patients, hemochromatosis is a complex genetic disease with strong environmental disease modifiers. Testing for mutations in the non-HFE hemochromatosis genes transferrin receptor 2, hemojuvelin, HAMP and SLC40A1 is complex, costly and time-consuming. Demonstration of hepatic iron overload by liver biopsy or MRI is therefore required before such complex tests are carried out. The pathogenesis of chronic liver disease in hemochromatosis is mainly attributed to the redox potential of tissue iron, and only the more recent studies have focused on the toxic properties of circulating iron. Considering the fact that an increased saturation of transferrin and high iron in plasma are the hallmark of all hemochromatosis forms, an alternative view would be that toxic iron in the circulation is involved in the pathogenesis of hemochromatosis. Recent studies have shown an increased concentration of redox-active iron in plasma in patients with increased transferrin saturation. This finding supports the hypothesis that tissue iron may be the 'smoking gun' of iron-induced organ damage. Taken together, caring for patients with suspected or established hemochromatosis still remains a challenge, where understanding the genetics, biochemistry and cell biology of hemochromatosis will aid better diagnosis and treatment of affected individuals.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27170390     DOI: 10.1159/000444549

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  4 in total

Review 1.  MR imaging assessment and quantification of liver iron.

Authors:  Manuela França; João Gomes Carvalho
Journal:  Abdom Radiol (NY)       Date:  2020-11

Review 2.  MRI Appearance of Focal Lesions in Liver Iron Overload.

Authors:  Anna Pecorelli; Paola Franceschi; Lorenzo Braccischi; Federica Izzo; Matteo Renzulli; Rita Golfieri
Journal:  Diagnostics (Basel)       Date:  2022-04-02

3.  VMP35 MNC, a novel iron-free supplement, enhances cytoprotection against anemia in human subjects: a novel hypothesis.

Authors:  Jean-Ronel Corbier; Bernard William Downs; Steve Kushner; Ted Aloisio; Debasis Bagchi; Manashi Bagchi
Journal:  Food Nutr Res       Date:  2019-05-09       Impact factor: 3.894

4.  Induction of homeostatic biological parameters in reward deficiency as a function of an iron-free multi-nutrient complex: Promoting hemoglobinization, aerobic metabolism, viral immuno-competence, and neuroinflammatory regulation.

Authors:  Kenneth Blum; Bernard W Downs; Manashi Bagchi; Steve Kushner; Bruce S Morrison; Jeffrey Galvin; Kourtney Randsdorp; Justin Randsdorp; Rajendra D Badgaiyan; Eric R Braverman; Debasis Bagchi
Journal:  J Syst Integr Neurosci       Date:  2020-06-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.